| Pawan Gupta: The Indian Air Force Serviceman and the Sanda Fighter | Pawan Hi-Flyer Sehrawat - The Present and Future of India's Kabaddi | Bikramjeet Singh: Here Everything You Wanted to Know About Biki Singh - India's first classic physique | All You Wanted to Know About the 'Khali' of Delhi Police Narender Yadav | Everything You Need to Know About Deepak The Indian Rock Nanda | Best Fruits for Weight Loss in 2024 | What Does Pre-Workout Supplements Do
A.DvorkinM.KulikovA
Disclosures: Babu Lal Meena: Nothing to Disclose, Shiv Kumar Sarin: Nothing to Disclose, Deepti Sharma: Nothing to Disclose 592 FIRST-IN-HUMAN PHASE 1 STUDY OF EA3571, WHICH IS A NOVEL DUAL INHIBITOR OF ENTEROPEPTIDASE AND TRYPSIN WITH LUMINAL ACTION, IN HEALTHY ADULT PARTICIPANTS ATSUSHI UMEDA 1 YASUKO OWADA 2 KENICHI FURIHATA 3 SHUICHI TSURUOKA 4 Atsushi Nakajima 5 RYOSUKE MIKAMI 6 MASAKAZE OAKU 1 TAKUYA YAMAMOTO 1 TETSUO YANO 1 YUJI KUMAGAI 7 , 1 EA Pharma Co., Ltd., 2 OPHAC Hospital, 3 P-one Clinic, 4 Tajirigaoka Hospital, 5 Yokohama City University, 6 EA Pharma Co., Ltd, 7 Kitasato Institute Hospital Background: EA3571 is a novel dual inhibitor of enteropeptidase and trypsin with luminal action
A database search of PubMed, Scopus and ClinicalTrials.gov was conducted using stem cells combined with intervertebral disc, degeneration and regeneration without exclusion based on publication date
TLR9 is localized in the endoplasmic reticulum prior to stimulation
